Plasma DNA mutation profiling for identifying predictors of treatment response
Liquid Biopsy refers to the analysis of tumor components that are realeased to the bloodstream. This includes nucleic acids (cell-free DNA and RNA), circulating tumor cells (CTCs) or extracellular vesicles (EVs). The current project aims at identifying predictors of response to systemic therapies by performing targeted mutation profiling of blood samples from patients with liver cancer, including sequential samples to monitor tumor evolution.
Role of EV-derived small RNA clusters during hepatocarcinogenesis
We previously found that small RNA clusters (smRCs) identified in blood extracellular vesicles (EVs) were capable to ditinguish patients with early liver cancer from controls and therefore serve as an early cancer detection tool. The current project aims at delineating the functional role of smRCs during hepatocarcinogenesis and to derive therapeutic strategies for cancer prevention.
Evolution of immune profiles on circulating EVs during immunotherapy
Extracellular vesicles (EVs) are known to function in cell-to-cell communication, including immune modulation. The current project aims at monitoring the evolution of immune check point profiles of cirulating EVs in the blood of patients undergoing immunotherapy.